| Aiko et al. (2011) |
Albania |
Difficulty and limitation in opening the mouth and pain in TMJ were seen in majority of systemic sclerosis but were observed in only one percent of cases of RA. Treatment was performed with NSAIDs, DMARDs and oral steroids. |
[66] |
| Rupareli et al. (2014) |
India |
TMD disorders can be diagnosed earlier based on RA related symptoms. Treatment was performed by administration of NSAIDs and corticosteroids. |
[67] |
| Sodhi et al. (2015) |
India |
TMD occurs in some cases of RA. Treatment was performed by administration of 75 mg methotrexate. |
[68] |
| Chebbi et al. (2016) |
Tunisia |
Early diagnosis of TMD is required in systemic sclerosis patients. Treatment was performed using conservative methods including rest, reassurance and jaw opening exercises as well as myorelaxants. |
[69] |
| Cordeiro et al. (2016) |
Brazil |
Diagnosis of TMD in RA patients is necessary in order to reduce structural and functional damages. Treatment was not mentioned in this article. |
[70] |
| Wang et al. (2017) |
Taiwan |
CIA is a suitable technique for assessment of RA related TMD. Treatment was not mentioned in this article. |
[71] |
| Crincoli et al. (2019) |
Italy |
The observations revealed that TMD was present in RA patients. Treatment was performed by the administration of corticosteroid, DMARDs and biologic DMARDs. |
[72] |
| Hutami et al. (2019) |
Japan |
TMJ has specific characteristic that distinguishes it from other joints. Therefore, there is a need for specific treatments for TMD. Blocking nuclear translocation of the p50 NF-κB subunit is a potential treatment option. |
[73] |
| Shi et al. (2003) |
China |
Hyaluronate was not significantly different from corticosteroids in the reduction of pain and other symptoms. Hyaluronate had potential effects in improving the arthroscopic assessment scores. Transient and mild complications, including discomfort or pain in the injection site, were reported in the hyaluronate group. |
[74] |
| Didem O. Ince et al. |
USA |
The results of this study revealed that treatment with methotrexate minimized joint destruction in TMD among rheumatoid arthritis patients. |
[75] |
| Sigvard Kopp et al. |
Sweden |
This study revealed that systemic treatment with combination of infliximab and methotrexate resulted in reduced TMJ related pain in patents with RA, which was correlated with increased cytokine levels and antidepressant receptors in the synovial fluid and plasma. |
[76] |
